Clinical Trial Update: Omega-3 Fatty Acid Adjunctive to Open-Label Aripiprazole for the Treatment of Bipolar Disorder in Children and Adolescents [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating omega-3 fatty acids as an add-on to open-label aripiprazole for pediatric bipolar disorder. The study was terminated and results were p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• ARIPIPRAZOLE (Aripiprazole)
• Omega-3 fatty acids (omega-3 fatty acids)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Pediatric Bipolar Disorder | Phase 4 | Status: TERMINATED | Results posted: 2012-04-06